drugset

Drugs / VAX-A1

Follow last change Jun 2026 re-read 3 minutes ago

VAX-A1

Developed for: streptococcus, group A, severity of infection by
Investigated by: Vaxcyte, Inc.

Trials 1

today NCT07616934 · Ph 1

20272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT07616934	Jun 2026 → Dec 2027 expected	streptococcus, group A, severity of infection by	Vaxcyte, Inc.	Recruiting	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2021-01-06	Vaxcyte, Inc.	Results Vaxcyte Announces Publication of Preclinical Proof-of-Concept Data Supporting Potential of VAX-A1, a Novel Conjugate Vaccine Designed to Prevent Group A Strep Infections vaxcyte.com ↗ The study demonstrated that active immunization of mice with the vaccine protected against a Group A Strep challenge in systemic infection and localized skin infection models.

All press releases naming this drug 3 releases

Date	Issuer	Release
2026-06-02	Vaxcyte, Inc.	Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults vaxcyte.com ↗
2021-08-05	Vaxcyte, Inc.	Vaxcyte Announces Expanded CARB-X Award to Advance Development of VAX-A1, a Vaccine to Prevent Group A Streptococcus Infections vaxcyte.com ↗
2021-01-06	Vaxcyte, Inc.	Vaxcyte Announces Publication of Preclinical Proof-of-Concept Data Supporting Potential of VAX-A1, a Novel Conjugate Vaccine Designed to Prevent Group A Strep Infections vaxcyte.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	VAX-A1	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07616934 ↗
Route	Intramuscular	“administered via intramuscular injection” NCT07616934 ↗